News

  • 17 April 2014

    Abbvie starts Phase III trial of lung cancer drug veliparib

    US-based biopharmaceutical firm AbbVie has started a global Phase III clinical trial of an investigational oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor 'veliparib (ABT-888)' in patients with previously untreated...

  • 10 April 2014

    Theravance starts Phase IIb trial of lung drug TD-4208

    US-based biopharmaceutical firm Theravance has started the dose-ranging Phase IIb trial (0117) of its investigational inhaled long-acting muscarinic antagonist (LAMA) TD-4208, as a nebulised aqueous solution for the treatment of...